Key Capital Seeks Partners for Development of KV-C19 Coronavirus Therapeutic Vaccine Using Proven Immunotherapy Platform
KV-C19 is believed to
have the potential to successfully treat COVID-19 and ARDS (acute respiratory
distress syndrome), the leading cause of COVID-19 deaths
Phoenix, Arizona - (NewMediaWire) - March 5, 2020 - KEY CAPITAL CORPORATION (OTC Pink: KCPC) advises its intention to explore partnering the
development of a collaborative therapeutic vaccine candidate, KV-C19, with
interested governments, agencies and investors. KV-C19 can be rapidly developed
for treatment of Coronavirus COVID-19 patients, and advanced ARDS (Acute
Respiratory Distress Syndrome) cases.
The opportunity is through an
immunotherapy technology platform collaboration that includes successfully
developed oral pill therapeutic vaccines that in patient studies have been
demonstrated to be highly effective in the treatment of terminal and late stage
cancers, TB, Hepatitis, and other serious conditions.
The rapidly spreading Coronavirus is close to
pandemic, as is being evidenced by its escalating spread in over 72 countries.
Its social and economic costs are already daunting; equity markets lost
approximately US$8 trillion in a little over a week; California yesterday,
followed Washington in announcing a state of emergency; country travel bans are
being activated; cities and factories in China have been shut down, as is also
the case with many industries, schools, conferences, sporting events etc. in
other countries; globally around 290 million children have seen their schools
close; airlines are grounding planes; Starbucks has stopped refilling coffee;
and the containment initiative reports keep coming in. The unfortunate reality
is if there is no significant breakthrough treatment soon, global economies
will further deteriorate dramatically as infection, deaths, and hardship
increase.
As at the time of writing, 97,837 people
globally have been infected with 3,347 deaths recorded, See: http://coronavirus-realtime.com/.
As there is currently no known treatment or cure for this Coronavirus, until a
vaccine and/or treatment is developed, containment and prevention are the only
way that the spread of the disease can at least be controlled to some
degree.
The KV-C19 therapeutic immunotherapy vaccine
development centers around the relatively new concept of using a therapeutic
vaccine to primarily treat a disease rather than preventing it. A therapeutic
immunotherapy vaccine treatment stimulates the body’s immunological system in
situations in which the body is insufficiently capable of developing an
effective response to disease cause. The proposed KV-C19 therapeutic
immunotherapy vaccine will be orally administered and absorbed through the
mucosa of the human gut. To the Company’s knowledge, the immunotherapy
treatment products developed to date are the only products demonstrating
success as an oral vaccine to treat terminal and late stage cancers, TB, and
many other serious conditions – and the only known treatment available as a
simple pill without side effects.
Of specific significance in the case of
COVID-19 is that almost all infectious viruses enter the host through mucous
membranes. Therefore, mucosal immunity, rather than systemic, is essential to
maximally protect against any such transmitted pathogens. The promise for
KV-C19 is that the oral therapeutic vaccine could confer treatment and local
immunity, not only at the site of delivery, but also on the surface of other
mucosal membranes. This could eventually also induce systemic immunity and see
the body’s own immune system kill the virus and enable the patient to achieve
full recovery.
“In the current situation, urgent treatment
intervention as soon as practically possible will not only save lives, but
significantly mitigate the risks of financial damage for many people
individually and for businesses and global economies,” said Key Capital
Corporation Chairman Mr. Peter Boonen. “We believe that we have a viable and
low-cost therapeutic solution that could potentially be available to a mass
global market in as little as six months. In the current situation, where the
Coronavirus threatens to become pandemic; where there is increasing global fear
and panic; where resources are being stretched to their limits; where the
economic cost is already in trillions of dollars; we believe we have something
to offer and that prospective partners will recognize we may well represent an
immediate potential solution.”
Mr. Boonen further advised; “To proceed in
this imperative initiative Key Capital will require partnered investment and,
therefore, welcomes inquiry and interest as through partnering with
stakeholders we can be production ready within months with possibly a most
viable and economically sensible solution.”
About Key
Capital Corporation
Key Capital is focused on the development of
social media and fintech interests. Key
Capital is also working with GoldVault, in which it has a 30% interest, to
prepare for a global launch of gold savings accounts in early 2020. The
GoldVault accounts will offer gold savings incentives through discounts and
rewards that provide the equivalent of 4.5% APY return in gold, which is up to
50 times the average savings account interest rate paid by most banks. See: www.goldvaultsaver.com
Development of the KV-C19 therapeutic vaccine
is through the Company’s Life Sciences division that the Company is planning to
spin-off in late 2020 or early 2021. See: https://keycapitalgroup.com/
For all inquiries please contact: Key Capital +1
(480) 745-2565
Peter Boonen, Chairman peter@keycapitalgroup.com or
Christopher Nichols chris@keycapitalgroup.com
Disclaimer: Statements made in
this press release that express the Company or management’s intentions, plans,
beliefs, expectations, or predictions of future events, are forward-looking
statements. The words “believe,” “expect,” “intend,” “estimate,” “anticipate,”
“will” and similar expressions are intended to further identify such
forward-looking statements, although not all forward-looking statements contain
these identifying words. Those statements are based on many assumptions and are
subject to many known and unknown risks, uncertainties and other factors that
could cause the Company’s actual activities, results or performance to differ materially
from those anticipated or projected in such forward-looking statements. The
Company cannot guarantee future financial results, levels of activity,
performance or achievements and investors should not place undue reliance on
the Company’s forward-looking statements.